Nuveen LLC Invests $168,000 in Inovio Pharmaceuticals, Inc. $INO

Key Points

• Nuveen LLC has invested approximately $168,000 in Inovio Pharmaceuticals, acquiring 103,297 shares and owning about 0.28% of the company.
• Several other hedge funds have also acquired stakes or increased their holdings in Inovio Pharmaceuticals, with 26.79% of the stock owned by institutional investors.
• Analysts have recently downgraded the stock's ratings, with price targets adjusted down to as low as $5.00, while Inovio currently holds a consensus rating of "Moderate Buy" with an average price target of $8.80.

Nuveen LLC acquired a new position in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 103,297 shares of the biopharmaceutical company's stock, valued at approximately $168,000. Nuveen LLC owned approximately 0.28% of Inovio Pharmaceuticals at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Alpine Global Management LLC bought a new stake in shares of Inovio Pharmaceuticals during the fourth quarter valued at approximately $31,000. Barclays PLC boosted its position in shares of Inovio Pharmaceuticals by 15.0% during the fourth quarter. Barclays PLC now owns 39,114 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 5,111 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Inovio Pharmaceuticals by 118.2% during the fourth quarter. Jane Street Group LLC now owns 39,704 shares of the biopharmaceutical company's stock worth $73,000 after purchasing an additional 21,512 shares in the last quarter. Concurrent Investment Advisors LLC bought a new position in shares of Inovio Pharmaceuticals during the first quarter worth $90,000. Finally, Graham Capital Management L.P. bought a new position in shares of Inovio Pharmaceuticals during the fourth quarter worth $114,000. 26.79% of the stock is owned by institutional investors.

Analysts Set New Price Targets

INO has been the topic of a number of research analyst reports. Zacks Research lowered shares of Inovio Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday. Oppenheimer lowered their price target on shares of Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 14th. Royal Bank Of Canada reiterated a "sector perform" rating and issued a $5.00 price target on shares of Inovio Pharmaceuticals in a research note on Wednesday, May 14th. Piper Sandler initiated coverage on shares of Inovio Pharmaceuticals in a research note on Wednesday, July 9th. They issued an "overweight" rating and a $5.00 price target on the stock. Finally, Wall Street Zen downgraded shares of Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, Inovio Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $8.80.

Inovio Pharmaceuticals Stock Performance

Shares of NASDAQ INO opened at $2.79 on Friday. Inovio Pharmaceuticals, Inc. has a 52-week low of $1.30 and a 52-week high of $7.00. The firm has a 50 day moving average price of $1.73 and a two-hundred day moving average price of $1.85. The stock has a market cap of $148.26 million, a P/E ratio of -1.07 and a beta of 1.62.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.02. Analysts predict that Inovio Pharmaceuticals, Inc. will post -4.23 earnings per share for the current fiscal year.

Inovio Pharmaceuticals Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Want to see what other hedge funds are holding INO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.